Effects of anti-hypertensive treatment on major cardiovascular events in populations within prehypertensive levels: a systematic review and meta-analysis

Journal of Human Hypertension
Zhongqiu HongDengfeng Geng

Abstract

Uncertainties still remain in terms of the efficacy of anti-hypertensive treatment on the risk of major cardiovascular (CV) events within prehypertensive levels. This review aims to assess the efficacy and safety of anti-hypertensives on the CV risks in populations within prehypertensive levels. Randomized controlled trials (RCTs) concerning active treatment vs placebo in populations within prehypertensive levels were identified through electronic database and manual search. Outcomes included the first co-primary outcomes, stroke, heart failure (HF), myocardial infarction (MI), all-cause mortality, and cardiovascular mortality. The first co-primary outcomes were defined as composite cardiovascular disease (CVD) events in the included studies. A total of 29 RCTs involving 127,641 participants were identified. Pooled analysis showed active treatment was associated with a significant 7% reduction in risk of the first co-primary outcomes, 14% in stroke, and 10% in HF as compared to placebo (0.86, 0.77-0.96; 0.93, 0.89-0.98; and 0.90, 0.83-0.97). However, there were no significant reductions in risk of MI, all-cause mortality, and cardiovascular mortality. A significant reduction in risk of the first co-primary outcomes was observed...Continue Reading

References

Sep 1, 1996·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·UNKNOWN PROGRESS Management Committee
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Feb 24, 2001·Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·E Eleuteri
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Sep 8, 2004·Lancet·Philip A Poole-WilsonUNKNOWN Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators
Oct 20, 2004·Circulation·Folkert W AsselbergsUNKNOWN Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Nov 13, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN CAMELOT Investigators
Apr 20, 2005·Hypertension·Ji-Guang WangFrançois Gueyffier
Jan 31, 2006·The American Journal of Medicine·Abhijit V KshirsagarRomulo E Colindres
Mar 16, 2006·The New England Journal of Medicine·Stevo JuliusUNKNOWN Trial of Preventing Hypertension (TROPHY) Study Investigators
May 11, 2006·Journal of Hypertension·Hisatomi ArimaUNKNOWN PROGRESS Collaborative Group
Sep 12, 2006·European Heart Journal·John G F ClelandUNKNOWN PEP-CHF Investigators
Sep 19, 2006·The New England Journal of Medicine·UNKNOWN DREAM Trial InvestigatorsRury R Holman
Feb 21, 2007·Circulation·Judith HsiaUNKNOWN Women's Health Initiative Investigators
Dec 12, 2007·Circulation·Jean L RouleauUNKNOWN IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators
Aug 12, 2008·Lancet·Syed Wamique Yusuf, Iyad N Daher
Aug 30, 2008·The New England Journal of Medicine·Salim YusufUNKNOWN PRoFESS Study Group
Nov 13, 2008·The New England Journal of Medicine·Barry M MassieUNKNOWN I-PRESERVE Investigators
Apr 17, 2009·The New England Journal of Medicine·Marcello DisertoriGianni Tognoni
Oct 3, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Lisheng LiuJiguang Wang
Jan 22, 2010·The New England Journal of Medicine·John J V McMurray
Jun 11, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Alok K GuptaWilliam D Johnson
Mar 3, 2011·JAMA : the Journal of the American Medical Association·Angela M ThompsonLydia A Bazzano
Mar 11, 2011·The New England Journal of Medicine·Hermann HallerUNKNOWN ROADMAP Trial Investigators
Mar 11, 2011·The New England Journal of Medicine·UNKNOWN ACTIVE I InvestigatorsStuart J Connolly
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Nov 6, 2012·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN ALTITUDE Investigators
Sep 4, 2013·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen
Dec 20, 2013·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Mar 14, 2014·Neurology·Yuli HuangDingli Xu

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

Stata
Review Manager

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.